Role of histamine H4 receptor ligands in bleomycin-induced pulmonary fibrosis. by Lucarini,  L. et al.
Durham Research Online
Deposited in DRO:
03 August 2016
Version of attached ﬁle:
Accepted Version
Peer-review status of attached ﬁle:
Peer-reviewed
Citation for published item:
Lucarini, L. and Pini, A. and Rosa, A.C. and Lanzi, C. and Durante, M. and Chazot, P.L. and Krief, S. and
Schreeb, A. and Stark, H. and Masini, E. (2016) 'Role of histamine H4 receptor ligands in bleomycin-induced
pulmonary ﬁbrosis.', Pharmacological research., 111 . pp. 740-748.
Further information on publisher's website:
https://doi.org/10.1016/j.phrs.2016.07.037
Publisher's copyright statement:
c© 2016 This manuscript version is made available under the CC-BY-NC-ND 4.0 license
http://creativecommons.org/licenses/by-nc-nd/4.0/
Additional information:
Use policy
The full-text may be used and/or reproduced, and given to third parties in any format or medium, without prior permission or charge, for
personal research or study, educational, or not-for-proﬁt purposes provided that:
• a full bibliographic reference is made to the original source
• a link is made to the metadata record in DRO
• the full-text is not changed in any way
The full-text must not be sold in any format or medium without the formal permission of the copyright holders.
Please consult the full DRO policy for further details.
Durham University Library, Stockton Road, Durham DH1 3LY, United Kingdom
Tel : +44 (0)191 334 3042 | Fax : +44 (0)191 334 2971
http://dro.dur.ac.uk
Accepted Manuscript
Title: Role of Histamine H4 Receptor ligands in
Bleomycin-induced pulmonary fibrosis
Author: Laura Lucarini Alessandro Pini Arianna Carolina
Rosa Cecilia Lanzi Mariaconcetta Durante Paul Louis Chazot
Ste´phane Krief Annemarie Schreeb Holger Stark Emanuela
Masini MD
PII: S1043-6618(16)30718-6
DOI: http://dx.doi.org/doi:10.1016/j.phrs.2016.07.037
Reference: YPHRS 3265
To appear in: Pharmacological Research
Received date: 30-5-2016
Revised date: 13-7-2016
Accepted date: 25-7-2016
Please cite this article as: Lucarini Laura, Pini Alessandro, Rosa Arianna
Carolina, Lanzi Cecilia, Durante Mariaconcetta, Chazot Paul Louis, Krief Ste´phane,
Schreeb Annemarie, Stark Holger, Masini Emanuela.Role of Histamine H4
Receptor ligands in Bleomycin-induced pulmonary fibrosis.Pharmacological Research
http://dx.doi.org/10.1016/j.phrs.2016.07.037
This is a PDF file of an unedited manuscript that has been accepted for publication.
As a service to our customers we are providing this early version of the manuscript.
The manuscript will undergo copyediting, typesetting, and review of the resulting proof
before it is published in its final form. Please note that during the production process
errors may be discovered which could affect the content, and all legal disclaimers that
apply to the journal pertain.
1 
 
Role of Histamine H4 Receptor ligands in Bleomycin-induced 
pulmonary fibrosis 
 
Laura Lucarini
1*
, Alessandro Pini
2*
, Arianna Carolina Rosa
3
, Cecilia Lanzi
1
, 
Mariaconcetta Durante
1
, Paul Louis Chazot
4
, Stéphane Krief
5
, Annemarie Schreeb
6
, 
 
Holger Stark
7
, Emanuela Masini
1
 
 
Running title: Histamine H4R ligands and pulmonary fibrosis 
 
Departments of 
1
NEUROFARBA, Section of Pharmacology, 
2
Experimental and Clinical Medicine, 
Section of Histology, 
3
Drug Science and Technology, University of Turin, Turin, Italy,
4 
School of 
Biological & Biomedical Sciences, Durham University, Durham, UK; 
5
Bioproject BIOTECH, 
Saint-Grégoire, France; 
6
Institute of Pharmaceutical Chemistry, Johann-Wolfgang Goethe 
University, Frankfurt, and  
7
Medicinal Chemistry, University of Dusseldorf, Dusseldorf, Germany.  
 
* Laura Lucarini and Alessandro Pini contributed equally 
 
Correspondence: 
Emanuela Masini, MD 
Department of NEUROFARBA, Section of Pharmacology 
University of Florence 
V.le G. Pieraccini n.6, 50139 Florence, Italy 
Phone: +39 055 2758199 
E-mail: emanuela.masini@unifi.it 
2 
 
 
Graphical Abstract 
 

3 
 
 
ABSTRACT 
 Fibrosis of lung tissue is a disease where a chronic inflammatory process determines a 
pathological remodelling of lung parenchyma. The animal model obtained by intra-tracheal 
administration of bleomycin in C57BL/6 mice is one of the most validated murine model.  
Bleomycin stimulates oxidative stress and the production of pro-inflammatory mediators. Histamine 
H4R have recently been implicated in inflammation and immune diseases. This study was focused 
to investigate the effects of H4R ligands in the modulation of inflammation and in the reduction of 
lung fibrosis in C57BL/6 mice treated with bleomycin. 
 C57BL/6 mice were treated with vehicle, JNJ7777120 (JNJ, selective H4R antagonist) or 
ST-1006 (partial H4R agonist), ST-994 (H4R neutral antagonist) and ST-1012 (inverse H4R agonist) 
at equimolar doses, released by micro-osmotic pumps for 21 days. Airway resistance to inflation 
was assayed and lung samples were processed to measure malondialdehyde (TBARS); 8-hydroxy-
2'-deoxyguanosine (8OHdG); myeloperoxidase (MPO); COX-2 expression and activity as markers 
of oxidative stress and inflammation. Fibrosis and airway remodelling were evaluated throughout 
transforming growth factor- (TGF- percentage of positive Goblet cells, smooth muscle layer 
thickness determination.  
Our results indicated that JNJ, ST-994 and ST-1012 decreased inflammation and oxidative stress 
markers, i.e. the number of infiltrating leukocytes evaluated as lung tissue MPO, COX-2 expression 
and activity, TBARS and 8OHdG production. They also reduced the level of TGF-, a pro-fibrotic 
cytokine, collagen deposition, thickness of smooth muscle layer, Goblet cells hyperplasia; resulting 
in a decrease of airway functional impairment. 
 The results here reported clearly demonstrated that H4R ligands have a beneficial effect in a 
model of lung fibrosis in the mouse, thus indicating that H4R antagonists or inverse agonists could 
be a novel therapeutic  strategy for lung inflammatory diseases.  
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Abbreviations: COX-2, Cyclooxygenase-2; H4R, Histamine H4 receptor; 8OHdG, 8-hydroxy-2'-
deoxyguanosine; JNJ7777120, 1-[(5-chloro-1H-indol-2yl)carbonyl]-4methylpiperazine; MPO, 
Myeloperoxidase; PGE2, Prostaglandin E2; ROS, Reactive oxygen species; TBARS, Thiobarbituric 
acid-reactive substances; TGFβ, transforming growth factor β; ST-994, N4-(4-methylbenzyl)-6-(4-
methylpiperazin-1-yl) pyrimidine-2,4-diamine; ST-1006, N
4
-(2,6-dichlorobenzyl)-6-
(methylpiperazin-1-yl) pyrimidine-2,4-diamine; ST-1012, N
4
-(1,3-dihydro-2H-isoindol-2-yl)-6-(4-
methylpiperazin-1-ylo) pyrimidine-2-amine.  
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1. Introduction 
 
 Lung fibrosis is a pathological response to chronic inflammation, which determines damage 
of epithelial cells, vascular exudation and infiltration of leukocytes in the alveolar spaces. 
The vascular exudate participates in the organization of extracellular tissue together with the 
proliferation of fibroblasts and their activation into myofibroblast and with the transdifferentiation 
of epithelial cells or the differentiation of circulating fibrocytes. Myofibroblasts, organized into 
aggregation of cells known as fibroblastic foci, are activated fibroblasts, secreting extra amount of 
connective tissue matrix and collagen, establishing the fibrotic process [1]. This process determines 
a progressive airway stiffening, making breathing difficult and leading to respiratory failure. 
Among the fibrotic diseases of the lung, idiopathic pulmonary fibrosis (IPF) is the most common 
and severe disease with a prevalence increasing every year [2,3] with a high mortality rate and a 
median survival of ~3 years [4]. At the moment, the available pharmacological treatments of IPF 
are usually symptomatic and not effective [5,6] and some patients require lung transplantation [5]. 
Anti-inflammatory agents, such as glucocorticoids or immunosuppressive drugs, have been the 
conventional pharmacological treatment, although current reviews suggest that there is no 
therapeutic benefit with these drugs in comparison with their significant side effects [7]. Therefore, 
novel treatment options, oriented towards novel substances and/or based on new therapeutic targets, 
are urgently required. Oxidative stress is thought to play an important role in the pathogenesis of 
lung inflammation, increasing neutrophil sequestration in the pulmonary microvasculature and gene 
expression of proinflammatory mediators [8]. Moreover, several lines of evidence confirm the 
involvement of mast cells in the pathogenetic mechanism of lung fibrosis [9,10]. The number of 
mast cells was found significantly increased both in lung biopsies from fibrotic patients [11] and in 
animal samples of bleomycin-induced pulmonary fibrosis [12], suggesting that mast cell mediators 
play an important role in inflammation and in smooth muscle cell hypertrophy, by secreting 
histamine, tryptase and growth factors [13]. Although the relationship between mast cells and tissue 
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remodelling remains not yet defined, it has been reported that the histamine released by mast cells 
contributes to the stimulation of other profibrotic stimuli, thus playing a role in the control of 
fibrotic process. Histamine is a pleiotropic mediator which exerts its biological effects through the 
activation of four different G-protein-coupled receptor subtypes (H1-4R) [14]. The H1R is involved 
in allergic and immune responses, the H2R regulates gastric acid secretion, the H3R, a presynaptic 
receptor mainly present in the Central Nervous System, controls neurotransmitter release [15], and 
the H4R, expressed in hematopoietic cells, activates mast cells, eosinophil and neutrophil migration 
[16,17]. Moreover, Kohyama and coworkers [18] demonstrated that the H4R mediates in vitro the 
profibrotic effects of histamine on human foetal lung fibroblasts. In fact, the histamine effect on 
potentiating fibronectin-induced lung fibroblast migration was blocked by the selective H4 
antagonist JNJ7777120 (JNJ). These data suggest that the histamine H4R could be a novel target for 
the development of new drugs for the treatment of lung inflammatory and fibrotic disease [18].  
 The aim of the present study was to evaluate whether H4R ligands could have a therapeutic 
effect in lung fibrosis [19,20]. To support the rationale of our hypothesis, we investigated the effects 
of different, novel, H4R ligands in controlling inflammation and fibrosis in an in vivo mouse model 
of bleomycin-induced pulmonary fibrosis. 
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2. Methods 
 
2.1. Characterization of histamine H4 receptor ligands in different screening models. 
 The affinity for histamine H4 receptors (H4R) was evaluated on 
3
[H]-histamine displacement 
assay on membrane preparation from Chinese hamster ovary (CHO)-K1 cells which stably express 
the human H4R and the efficacy was evaluated on functional binding assay using
 35
[S] GTPyS on 
membrane preparation from stable CHO-hH4R. Functional gene reporter assay was performed in 
CHO-dukx cells stably expressed both the mouse H4R and luciferase gene under the control of 
MRE/CRE responsive elements [21] and stimulated by forskolin 0.3 μM. Reference full agonist for 
efficacy was imetit in the mouse H4R gene reporter assay. pKi for histamine H1 receptors (H1R) was 
determined with 
3
[H]-pyrilamine displacement assay on membrane preparation from CHO-K1 cells 
stably expressing the human H4R [22] and on Sf9 cell membranes co-expressing hH1R and RGS4 
[23]; pKi for histamine H2 receptors (H2R) was determined with 
3
[H]-tiotidine displacement assay 
on Sf9 cell membranes with hH2R-Gsαs fusion protein [23]; pKi for histamine H3 receptors (H3R) 
was performed with 
3
[H]N
α
-methylhistamine displacement  on Sf9 cell membranes co-expressing 
hH3R, Gαi2, Gβ1γ2 and RGS4 [23]. Ki(s) were calculated according to Cheng and Prusoff [24].  
 
2.2. Animals 
 Male C57BL/6 mice, approximately 2 months old and weighing 25 to 30 g, were used for 
the experiments. They were purchased from a commercial source (Harlan, Udine, Italy), fed a 
standard diet, and housed for at least 48 h under a 12-h light/dark photoperiod before the 
experiments. The study protocol complied with the Declaration of Helsinki and the 
recommendations of the European Economic Community (86/609/CEE) on animal experimentation 
and was approved by the animal care committee of the University of Florence (Florence, Italy). 
Experiments were carried out at the Centre for Laboratory Animal Housing and Experimentation, 
8 
 
University of Florence. All studies involving animals are reported in accordance with the ARRIVE 
guidelines for reporting experiments involving animals [25,26]. 
 
2.3. Surgery and treatments 
 Fifty six mice were anesthetized with zolazepam/tiletamine (Zoletil, Virbac Srl, Milan, Italy; 
50 μg/g i.p. in 100 μl of saline); 50 of them were treated with bleomycin (0.05 IU in 100 μl of 
saline), and the other six were treated with 100 μl of saline (referred to as non fibrotic negative 
controls, Saline), both delivered by intra-tracheal injection. Six mice did not undergo to surgery and 
used as control (Naïve).   
 The bleomycin treated mice, ten per group, were treated with continuous infusion of H4R 
ligands by osmotic micropumps (Alzet, Cupertino, CA, USA) filled with 100 l of PBS pH 7.4, 
containing the H4R ligands at the reported concentrations: JNJ7777120 40 mg/kg; ST-994 53 
mg/kg; ST-1006 60 mg/kg; ST-1012 53 mg/kg. Ten mice were treated only with PBS and referred 
to as fibrotic positive controls (Vehicle). The micropumps were implanted subcutaneously into a 
dorsal poach at day 0 and maintained for 21 days. They released 1.55 l per day. 
 
2.4. Functional assay of fibrosis 
 At day 21 after surgery, the mice were subjected to measurement of airway resistance to 
inflation, a functional parameter related to fibrosis-induced lung stiffness, by using a constant 
volume mechanical ventilation method [27,28]. In brief, upon anaesthesia, the mice were operated 
on to insert a 22-gauge cannula (Venflon 2; Viggo Spectramed, Windlesham, UK, 0.8 mm 
diameter) into the trachea and then ventilated with a small-animal respirator (Ugo Basile, Comerio, 
Italy), adjusted to deliver a tidal volume of 0.8 ml at a rate of 20 strokes/min. Changes in lung 
resistance to inflation, defined as pressure at the airway opening (PAO), were registered by a high-
sensitivity pressure transducer (P75 type 379; Harvard Apparatus Inc., Holliston, MA) connected to 
a polygraph (Harvard Apparatus Inc. Edenbridge, UK; settings: gain 1, chart speed 25 mm/s). 
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Changes in lung resistance to inflation (PAO), measured for at least 3 min and expressed as 
millimetres, were carried out on at least 40 consecutive tracings of respiratory strokes and then 
averaged. 
 
2.5. Lung tissue sampling 
 After the functional assay, the animals were killed with an overdose of anesthetic, and the 
whole left lungs were excised and fixed by immersion in 4% paraformaldehyde in phosphate-
buffered saline for histological analysis. The right lungs were weighed, quickly frozen, and stored at 
−80°C. When needed for the biochemical assays, these samples were thawed at 4°C, homogenized 
on ice in 50 mM Tris-HCl buffer containing 180 mM KCl and 10 mM EDTA, pH 7.4, and then 
centrifuged at 10,000g, 4°C, for 30 min, unless otherwise reported. The supernatants and the pellets 
were collected and used for separate assays as detailed below. 
 
2.6. Histology and assessment of collagen deposition, Goblet cell hyperplasia, and smooth muscle 
layer thickness 
 Histological sections, 6 μm thick, were cut from the paraffin-embedded lung samples. All 
sections were stained in a single session to minimize artifactual differences in the staining. 
Photomicrographs of the histological slides were randomly taken with a digital camera connected to 
a light microscope equipped with a x10 or x40 objective. Quantitative assessment of the stained 
sections was performed by computer-aided densitometry. Measurements of optical density (OD) 
and surface area were carried out using the free-share ImageJ 1.33 image analysis program 
(http://rsb.info.nih.gov/ij). 
 For assessment of lung collagen, the sections were stained with a simplified Azan method 
for collagen fibers according to Smolle et al., [29] with minor modifications, in which 
azocarminium and orange G were omitted to reduce parenchymal tissue background. OD 
measurements of the aniline blue-stained collagen fibers were carried out upon selection of an 
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appropriate threshold to exclude aerial air spaces and bronchial/alveolar epithelium, according to 
Formigli et al. [30]. Values are means ± SEM of the OD measurements (arbitrary units) of 
individual mouse (five images each) from the different experimental groups. 
 For morphometry of smooth muscle layer thickness and bronchial Goblet cell number, both 
key markers of airway remodelling, lung tissue sections were stained with hematoxylin and eosin or 
with periodic acid-Schiff (PAS) staining for mucins, respectively. Digital photomicrographs of 
medium- and small-sized bronchi were taken at random. Measurements of the thickness of the 
bronchial smooth muscle layer were carried out on the digitized images using the above-mentioned 
software. PAS-stained Goblet cells and total bronchial epithelial cells were counted on bronchial 
cross-section profiles, and the percentage of Goblet cells was calculated. For both parameters, 
values are means ± SEM of individual mouse (five images each) from the different experimental 
groups (tested blind). 
 
2.7. Western blot analysis for H4R and COX-2 protein expression 
 The total protein for the lung samples were obtained as described previously [31]. Lung 
tissues were lysed with buffer containing 0.9% NaCl, 20 mmol/L Tris-HCl (pH 7.6), 0.1% Triton 
X-100, 1 mmol/L phenylmethylsulfonyl fluoride, and 0.01% leupeptin, and homogenized. The total 
proteins (80 g) as evaluated with the use of a bicinchoninic acid protein assay were subjected to 
Western blot and immunoblotting analysis as previously described [32]. The loading transfer of 
equal amounts of proteins were ascertained by either reblotting the membrane with an anti-tubulin 
antibody and/or staining the membrane with Ponceau S. The primary antibodies used were anti-H4R 
polyclonal antibody (1,5 µg/mL, ab97997, Abcam, Cambridge, UK), anti-COX-2 polyclonal 
antibody (1:500, sc7951, Santa Cruz, Dallas, Texas, USA) and anti- actin goat polyclonal antibody 
(1:500; ab8229, Abcam, Cambridge, UK). The binding of each primary antibody was determined 
by the addition of suitable peroxidase-conjugated secondary antibodies (anti-goat and anti-rabbit 
antibodies 1:15000). Densitometric analysis was performed with the ImageJ software. 
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2.8. Determination of myeloperoxidase (MPO) 
 This tissue indicator of leukocyte recruitment was determined in aliquots (100 μl) of lung 
homogenate supernatants, using a commercial ELISA kit (CardioMPO; Prognostix Inc., Cleveland, 
OH, USA), according to the manufacturer's instructions. The values are expressed as mU/mg of 
lung tissue (wet weight). 
 
2.9. Determination of Prostaglandin E2 (PGE2) 
 The levels of PGE2, the major cyclooxygenase product generated by activated inflammatory 
cells, were measured in aliquots (100 μl) of lung homogenate supernatants by using commercial 
ELISA kits (Cayman Chemical, Ann Arbor, MI), following the protocol provided by the 
manufacturer. The values are expressed as ng/mg of proteins, the latter determined with the 
Bradford method [32]. 
 
2.10. Determination of thiobarbituric acid-reactive substances (TBARS) 
 TBARS, such as malondialdehyde, are end-products of cell membrane lipid peroxidation by 
reactive oxygen species (ROS) and are considered reliable markers of oxidative tissue injury. They 
were determined by the measurement of the chromogen obtained from reaction of TBARS with 2-
thiobarbituric acid [33]. In brief, 0.5 ml of 2-thiobarbituric acid (1% w/v) in 50 mM NaOH and 0.5 
ml of HCl (25% w/v in water) were added to the lung tissue pellets. The mixture was placed in test 
tubes, sealed with screw caps, and heated in boiling water for 10 min. After cooling, the chromogen 
was extracted in 3 ml of 1-butanol, and the organic phase was separated by centrifugation at 2,000 g 
for 10 min. The absorbance of the organic phase was read spectrophotometrically at 532 nm 
wavelength over a standard curve of 1,1,3,3-tetramethoxypropane. The values are expressed as 
ng/mg of proteins, the latter determined as previously described [32]. 
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2.11. Determination of 8-hydroxy-2'-deoxyguanosine (8OHdG) 
 Frozen lung samples were thawed at room temperature, and cell DNA isolation was 
performed as previously described [34] with minor modifications. The samples were homogenized 
in 1 ml of 10 mM PBS, pH 7.4, sonicated on ice for 1 min, added to 1 ml of 10 mM Tris-HCl 
buffer, pH 8, containing 10 mM EDTA, 10 mM NaCl, and 0.5% SDS, and incubated for 1 h at 37°C 
with 20 μg/ml RNase. Samples were incubated overnight at 37°C in the presence of 100 μg/ml 
proteinase K. Afterwards, the mixture was extracted with chloroform/isoamyl alcohol (10:2 v/v). 
DNA was precipitated from the aqueous phase with 0.2 volume of 10 M ammonium acetate, 
solubilized in 200 μl of 20 mM acetate buffer, pH 5.3, and denaturated at 90°C for 3 min. The 
extract was then supplemented with 10 IU of P1 nuclease in 10 μl and incubated for 1 h at 37°C 
with 5 IU of alkaline phosphatase in 0.4 M phosphate buffer, pH 8.8. All the procedures were 
performed in the dark. The mixture was filtered by an Amicon Micropure-EZ filter (Millipore 
Corporation, Billerica, MA), and 100 μl of each sample were used for 8OHdG determination by 
using an ELISA kit (JalCA, Shizuoka, Japan), following the instructions provided by the 
manufacturer. The values are expressed as ng/mg of proteins, the latter determined as previously 
reported [32]. 
 
2.12. Determination of Transforming Growth Factor-β (TGF-)  
 The levels of TGF-β, the major profibrotic cytokine involved in fibroblast activation [35], 
were measured on aliquots (100 μl) of lung homogenate supernatants by using the Flow Cytomix 
assay (Bender Medsystems GmbH, Vienna, Austria), following the protocol provided by the 
manufacturer. In brief, suspensions of anti-TGF-β-coated beads were incubated with the samples 
and with a TGF-β standard curve, and then with biotin-conjugated secondary antibodies and 
streptavidin-phycoerythrin. Fluorescence was read with a cytofluorimeter (Epics XL; Beckman 
Coulter, Milan, Italy). Values are expressed as pg/g of protein, determined as previously reported 
[32]. 
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2.13. Statistical Analysis 
 For each assay, data were reported as mean values (± SEM) of individual average measures 
of the different animals per group. Significance of differences among the groups was assessed by 
one-way ANOVA followed by Newman-Keuls post hoc test for multiple comparisons, or, when 
only two groups had to be compared, by Student's t test for unpaired values. Calculations were 
made with Prism 4.03 statistical software (GraphPad Software, Inc., San Diego, CA,USA). 
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3. Results 
3.1. Functional assay of fibrosis 
 Intra-tracheal bleomycin caused a statistically significant increase in airway stiffness, as 
showed by the clear-cut elevation in the pressure at airway opening (PAO) in the fibrotic positive 
controls given vehicle (14.67 ± 0.08 mm) compared with the non-fibrotic negative controls (12.43 ± 
0.40 mm). Both compounds JNJ and ST-994, two selective antagonists of histamine H4R, and ST-
1012, an inverse agonist, caused a statistically significant reduction of airway stiffness (13.16 ± 
0.38, 13.11 ± 0.42 mm and 12.5 ± 0.49, respectively). The results of the functional assay are 
reported in Figure 1. No effects were shown with ST-1006, a partial agonist (14,36 ± 0,37) (Fig. 1). 
 
3.2. Expression of histamine H4 receptor in lung tissue 
 The administration of bleomycin caused a statistically significant increase in the H4R protein 
expression in lung homogenates. The increased expression of H4R protein was significantly reduced 
in lung samples obtained from JNJ-treated animals. All the other studied ligands determined a 
decrease in H4R protein expression although did not reach statistical significance (Fig. 2, panel A 
and B). 
 
3.3. Effects of H4 Receptor ligands on inflammation and oxidative stress markers 
 Intra-tracheal bleomycin injection was found to cause lung inflammation. The extent of 
inflammatory infiltrate in the lung, mainly macrophages and neutrophils, was significantly 
increased in positive control animals after bleomycin administration as shown by the increase in 
MPO activity (Fig. 3). The treatment of the animals with all the selected H4R ligands caused a 
statistically significant reduction of MPO activity.  
 To gain further insight into the effects of the different H4R ligands on inflammation, COX-2 
expression and activity were evaluated. As expected, all the H4R ligands studied reduced 
bleomycin-induced COX-2 expression (Fig. 4, panel A). This effect resulted also in a significant 
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reduction of PGE2 production, the major COX-2 product generated by activated inflammatory cells 
(Fig. 4, panel B), obtained with the two antagonists (JNJ and ST-994) and with the inverse agonist 
(ST-1006). The production of MDA was  evaluated as TBARS (Fig. 5, panel A), end-products of 
cell membrane lipid peroxidation by ROS and reliable markers of oxidative tissue injury. The 
production of TBARS was markedly increased in the fibrotic positive control compared with non-
fibrotic negative one. As shown in Fig. 5, panel A, only the antagonists JNJ and ST-994 and the 
inverse agonist ST-1012 significantly reduced TBARS production.  
 Determination of 8OHdG (Fig. 5 panel B), an indicator of oxidative DNA damage, showed a 
similar trend as TBARS, markedly increased in the fibrotic positive control compared with the non-
fibrotic one. The administration of JNJ, ST-994 and ST-1012 significantly reduced 8OHdG 
production. ST-1006 treatment did not affect TBARS and 8OHdG level. 
 
3.4. Effects of H4R ligands on fibrosis 
 The assay of TGF- (Fig. 6), a major pro-fibrotic cytokine, showed that this molecule  
significantly increased in the bleomycin-treated animals as compared with the controls. 
Administration of all the selected histamine H4R ligands caused a statistically significant reduction 
of TGF-production. Morphological observation and computer-aided densitometry on Azan-
stained sections (Fig. 7), which allows the determination of the optical density (OD) of collagen 
fibers, revealed a significant increase in collagen deposition in the lungs of the bleomycin-treated 
animals compared with the non-fibrotic negative controls. The treatment with JNJ, ST-994 and ST-
1012 caused a robust, near complete, reduction of the amount of lung collagen fibers (Fig. 7, panel 
B). No effects were shown with ST-1006.  
 Bronchial remodeling was evaluated by measuring the relative number of PAS-positive 
Goblet cells (Fig. 8, panel A) and thickness of the smooth muscle layer (Fig. 8, panel B), key 
histological parameters of inflammation-induced adverse bronchial remodeling [36]. As expected, 
both these parameters were significantly increased in the bleomycin-treated mice. Notably, all the 
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tested compounds were able to significantly reduce the percentage of PAS-positive Goblet cells 
versus total bronchial epithelial cells (Fig. 8, panel A), as well as the thickness of the airway smooth 
muscle layer (Fig. 8, panel B). Although, the compound ST-1006 was less effective. 
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4. Discussion 
 The results here reported clearly demonstrated that H4R ligands have a beneficial effect in a 
model of lung fibrosis in the mouse. In our experiments, the H4R ligands were administered in a 
preventive mode. Compound JNJ, a selective H4R antagonist, ST-994, a H4R neutral antagonist and 
ST-1012, an inverse H4R agonist, displayed robust anti-inflammatory and anti-fibrotic properties: in 
fact they consistently decreased markers of inflammation and oxidative stress, i.e. the number of 
infiltrating leukocytes evaluated as lung tissue MPO, COX-2 expression and activity, TBARS and 
8OHdG production. They also reduced the level of TGF-, a pro-fibrotic cytokine, collagen 
deposition, thickness of smooth muscle layer, Goblet cells hyperplasia; resulting in a decrease of 
airway resistance to inflation (PAO). The involvement of histamine in human lung fibrosis is 
indicated by the increased number of mast cells in the lung of patients affected by lung fibrosis in 
comparison to control subjects and their correlation with the severity of the disease [37]. Histamine 
concentration in the BAL fluid of IPF patients is 10-fold increased respect to the healthy subjects 
[38,39], and histamine stimulates human lung fibroblast migration through H4R, [18]. Taken 
together, these evidences suggest that histamine and histaminergic H4R receptor are involved in 
lung inflammation and fibrosis development. On the other hand, in bleomycin-induced animal 
model of lung fibrosis, naproxen and NO-donating naproxen (CINOD), two classic anti-
inflammatory drugs, determined a significant reduction of lung inflammation and consequent 
fibrosis [28].  
 It is well known that chronic inflammation in the lung determines permanent alteration of 
lung structure characterized by airway epithelium modification and fibrosis. Indeed, the treatment 
with bleomycin activates the inflammatory cascade, as clearly underlined by the increase in MPO 
activity, histamine H4R and COX-2 protein expression and activity (Fig. 2, 3 and 4), indicating an 
increase in the number of inflammatory cells migrated to the lung parenchyma. Histamine is 
implicated in the physiopathology of several inflammatory and immunological mechanisms, acting 
in both the acute and chronic phase. The function of histamine in cellular immunity, through the 
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control of cytokine and chemokine production and migration of inflammatory cells, beyond its 
traditional role in mediating fast airway hyper-responsiveness, has been defined [40]. In a mouse 
model of zymosan-induced peritonitis, histamine H4R ligands exerted anti-inflammatory activity 
[41,42]. In this model, intra-peritoneal treatment of mice with zymosan induces neutrophil 
migration, which is blocked by an H4R antagonist [43]. Accumulating experimental evidence 
indicates the role of H4R in modulating lung inflammation, mainly through its effects on Th2 cell 
induction [44]. 
 In a model of dermal inflammation, pro-inflammatory cytokines, such as IL-4 and 
chemokines, were increased in ear tissue on fluorescein isothiocyanate (FITC) challenge, an effect 
significantly reduced with the treatment with H4R antagonists [45]. The  administration of JNJ 
dose-dependently reduced the ear edema and the scratching response [46]. In a rat model of 
carrageenan-induced acute inflammation, H4R antagonists decreased the formation of edema [28] 
and, in the early phase, significantly reduced the hyperalgesia consequent to thermal stimulation, 
controlling peripheral nociceptive pathway [47]. Histamine H4R is functionally expressed in cells of 
immune system [48] including NK cells, dendritic cells (DCs) and monocytes, although the 
expression of this receptor in monocytes is still controversial. Zhu et al.,[49] demonstrated a very 
low expression of H4R in resting CD14
+ 
cells, other authors only in activated monocytes [50] or in 
THP-1 clone 15 cells, which highly secret TNFα and IL-1, which in turn might induce the 
expression of H4R [48]. The presence of H4R protein in cells of the innate immunity could explain 
how these cells localize at inflammation sites and justify the anti-inflammatory activity of H4R 
antagonists. Indeed histamine is a robust chemotactic factor for these cells [48]. 
 Our results highlighted that H4R antagonists or inverse agonists inhibit the production of 
TGF-, a pro-fibrotic cytokine and a recent identified target for the development of novel anti-
fibrotic agents. Drugs controlling the formation and activity of TGF-, such as anti-TGF- 
monoclonal antibodies and pirfenidone, a drug which inhibit fibroblast activation, hold great 
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promise and were subject to clinical development [51]; however, their therapeutic efficacy on 
patients with lung fibrosis, especially IPF, still remains to be clearly defined [52]. On the other 
hand, the strategy of targeting prostaglandin synthesis by COX inhibitors is still controversial. In 
fact, patients with pulmonary fibrosis have decreased PGE2 levels and may benefit from prostanoid 
administration [53]. There is still an unmet need for selective, potent, avoided of side-effects and 
safe anti-fibrotic drugs. The results here reported suggest H4R ligands as novel therapeutic agents 
endowed with anti-inflammatory and anti-fibrotic activities, when administered in the inflammatory 
phase of the fibrotic onset. ST-1006, a partial agonist of H4R, exerted only some beneficial effect. 
This result could be explained considering the intrinsic activity of all histaminergic receptors and in 
particular H4R [54] 
 In conclusion, the dual effect of H4R ligands on inflammation and fibrosis pathways, 
indicates their therapeutic potential for inflammatory and immune diseases, including idiopatic 
pulmonary fibrosis. 
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Legends 
 
Fig. 1 
Spirometric evaluation. Bar graph and statistical analysis of PAO values (means ± SEM.) among 
the different experimental groups. Significance of differences (one-way ANOVA and Newman–
Keuls post hoc test): *p < 0.05  vs Bleomycin + Vehicle. 
 
Fig. 2 
Western blot analysis of H4R expression in the lung specimens from the different experimental 
groups (Panel A). The densitometric analysis of the bands was normalized to β-actin (Panel B). 
Data are representative of at least three independent experiments. Significance of differences (one-
way ANOVA and Newman–Keuls post hoc test): **p<0.01 vs Bleomycin + Vehicle. 
 
Fig. 3 
Evaluation of leukocyte infiltration. Bar graph shows MPO levels in the lung tissue (means ± SEM) 
of the different experimental groups. Significance of differences (one-way ANOVA and Newman–
Keuls post hoc test): **p<0.01 and ***p<0.001 vs Bleomycin + Vehicle. 
 
Fig. 4 
Western blot analysis of COX-2 expression in the lung specimens from the different experimental 
groups (Panel A). The densitometric analysis of the bands was normalized to β-actin (Panel B). 
Data are representative of at least three independent experiments. Prostaglandin production: bar 
graph shows the lung tissue levels of PGE2 (means ± SEM) of the different experimental groups 
(Panel C). Significance of differences (one-way ANOVA and Newman–Keuls post hoc test): 
*p<0.05, **p<0.01 and ***p<0.001 vs bleomycin + vehicle. 
 
Fig. 5 
Evaluation of oxidative stress parameters. Bar graphs shows the lung tissue levels of TBARS (Panel 
A) and 8OHdG (Panel B) of the different experimental groups (means ± SEM). Significance of 
differences (one-way ANOVA and Newman–Keuls post hoc test): *p<0.05, **p<0.01 and 
***p<0.001 vs Bleomycin + Vehicle. 
 
Fig. 6 
Evaluation of TGF-β. Bar graph shows the lung tissue levels of the profibrotic cytokine (means ± 
SEM) of the different experimental groups.  Significance of differences (one-way ANOVA and 
Newman–Keuls post hoc test): ***p<0.001 vs Bleomycin + Vehicle. 
 
Fig. 7 
Evaluation of lung fibrosis. Representative micrographs of Azan-stained lung tissue sections from 
mice of the different experimental groups. Collagen fibers are deep blue stained. The lung from a 
fibrotic positive control shows marked fibrosis, which is absent in the lung from a non-fibrotic 
negative control and reduced by all the treatments. Scale bars, 50 m. Densitometric analysis of 
Azan-stained sections is shown in bar graph as arbitrary OD units (means ± SEM). Significance of 
differences (one-way ANOVA and Newman–Keuls post hoc test): ***p<0.001 vs Bleomycin + 
Vehicle. 
 
Fig. 8 
Evaluation of Goblet cell hyperplasia (Panel A) and bronchial smooth muscle layer thickness (Panel 
B), shown as both the representative micrographs of the stained section and the relative 
densitometric analyses. The Goblet cells hyperplasia was measured by PAS staining and computer-
aided morphometry in lung specimens of the different experimental group. The PAS-positive cells 
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are indicated by arrows. The histograms show the percentage of PAS-positive Goblet cells over 
total epithelial cells (means ± SEM) (Panel A). The smooth muscle thickness was assessed by 
computer-aided morphometry on hematoxylin and eosin-stained lung sections in lung specimens of 
the different experimental groups and indicated by double arrows. The histograms show the 
thickness of the smooth muscle (means ± SEM) (Panel B). Significance of differences (one-way 
ANOVA and Newman–Keuls post hoc test): *p<0.05 and **p<0.01 vs Bleomycin + Vehicle. Scale 
bar, 50 m.  
 
Fig. 1
Fig. 2
Fig. 3
Figure 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
